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Abstract 
Lafora progressive myoclonus epilepsy (Lafora disease, LD) is a fatal rare autosomal 
recessive neurodegenerative disorder characterized by the accumulation of insoluble 
ubiquitinated polyglucosan inclusions in the cytoplasm of neurons, which is most 
commonly associated with mutations in two genes: EPM2A, encoding the glucan 
phosphatase laforin, and EPM2B, encoding the E3-ubiquitin ligase malin. The present 
study analyzes possible inflammatory responses in the mouse lines Epm2a-/- (laforin 
knock-out) and Epm2b-/- (malin knock-out) with disease progression. Increased 
numbers of reactive astrocytes (expressing the GFAP marker) and microglia 
(expressing the Iba1 marker) together with increased expression of genes encoding 
cytokines and mediators of the inflammatory response occur in both mouse lines 
although with marked genotype differences. C3ar1 and CxCl10 mRNAs are 
significantly increased in Epm2a-/- mice aged 12 months when compared with age-
matched controls, whereas C3ar1, C4b, Ccl4, CxCl10, Il1b, Il6, Tnfα and Il10ra mRNAs 
are significantly up-regulated in Epm2b-/- at the same age. This is accompanied by 
increased protein levels of IL1-β, IL6, TNFα and Cox2 particularly in Epm2b-/- mice. The 
severity of inflammatory changes correlates with more severe clinical symptoms 
previously described in Epm2b-/- mice. These findings show for the first time increased 
innate inflammatory responses in a neurodegenerative disease with polyglucosan 
intraneuronal deposits which increase with disease progression, in a way similar to 
what is seen in neurodegenerative diseases with abnormal protein aggregates. These 
findings also point to the possibility of using anti-inflammatory agents to mitigate the 
degenerative process in LD. 
 
 
Key words: Lafora disease, polyglucosan, inflammation, cytokines, chemokines, 
microglia   
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Introduction 
 
Lafora progressive myoclonus epilepsy (Lafora disease, LD, OMIM 254780, 
ORPHA501) is a fatal rare autosomal recessive neurodegenerative disorder, which 
usually occurs during childhood. It is characterized by generalized tonic-clonic 
seizures, myoclonus, absences, drop attacks and visual seizures. As the disease 
progresses, patients present a rapid progressive dementia concomitant with an 
amplification of seizures, leading to death within a decade after the first symptoms [1, 
2]. The hallmark of the disease is the accumulation of insoluble polyglucosan 
inclusions, called Lafora bodies (LBs), in the cytoplasm of neurons and other cells in 
peripheral tissues. In the vast majority of patients LD has been associated with 
mutations in two genes: EPM2A, encoding the glucan phosphatase laforin, and 
EPM2B, encoding the E3-ubiquitin ligase malin. Although laforin and malin may have 
independent functions, it has been shown that they form a functional complex in which 
laforin acts as scaffold and recruits specific substrates to be ubiquitinated by malin. It 
has also been demonstrated that laforin and malin regulate glycogen synthesis, either 
by affecting the activity of proteins involved in this process [3-6] or by laforin’s acting as 
a glycogen phosphatase and thus being able to dephosphorylate complex glucans [7-
9]. This would explain why the absence of laforin or malin leads to aberrant glycogen 
accumulation in neurons in the form of LBs, which are glycogen-like inclusions with a 
greater degree of phosphorylation and less branching than normal glycogen. Hence 
LBs are largely insoluble. 
Recent work has demonstrated that neuronal death in LD can be influenced not only by 
the accumulation of LBs but also by impairment in mechanisms related to protein 
clearance. For instance, endoplasmic reticulum stress is significantly increased in 
mouse models of LD [10-13], and molecular interactions between laforin, malin and the 
chaperone and proteasome systems [14, 15] have been described. This body of 
evidence points to a critical dysregulation of cellular protein homeostasis in LD that 
goes beyond alterations in glycogen metabolism regulation. In this sense, our previous 
work with mouse models of LD such as Epm2a-/- [16] and Epm2b-/- [17] revealed 
impairment of autophagy and defects in the ubiquitin-proteasome system [12, 18] 
which correlated with neurological and behavioral abnormalities. We have also 
described increased oxidative stress and impaired antioxidant response in LD cellular 
and mouse models [19], thus suggesting that oxidative stress is a new hallmark in the 
pathogenesis of LD [20]. These results are in agreement with the hypothesis that 
defects in autophagy and protein clearance are related with an increase in reactive 
oxygen species (ROS) production and consequent oxidative stress [21-24]. It is 
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feasible that alterations in protein homeostasis and oxidative stress could underlie the 
appearance of reactive astrogliosis observed in different brain areas of malin knock-out 
(Epm2b-/-) mice [25, 26]. Microglia activation and neuroinflammatory responses are 
currently observed in most neurodegenerative diseases and they are determinants in 
the pathogenesis of these processes [27-30]. However, very little is known about 
inflammatory responses and most particularly about gene modulation of cytokines and 
mediators of the immune response along with disease progression in LD. The present 
study is focused on possible inflammatory responses in the brain of laforin knock-out 
(Epm2a-/-) and malin knock-out (Epm2b-/-) mice to learn whether inflammation plays a 
role in the pathogenesis of LD, in the same way that inflammation has functional 
implications in the pathogenesis of neurodegenerative diseases with abnormal protein 
aggregates. 
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Material and methods 
 
Ethical statement, animal care, mice and husbandry 
This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the Consejo Superior de Investigaciones 
Cientificas (CSIC, Spain). All mouse procedures were approved by the animal 
committee of the Instituto de Biomedicina de Valencia-CSIC [Permit Number: INTRA12 
(IBV-4)]. All efforts were made to minimize animal suffering. To eliminate the effect of 
differences in the genetic background of the animals, we backcrossed Epm2a-/- and 
Epm2b-/- mice (with a mixed background 129sv:C57BL/6) as previously described [16, 
17, 31]) with control C57BL/6JRccHsd mice obtained from Harlan laboratories 
(Barcelona, Spain) ten times to obtain homozygous Epm2a-/- and Epm2b-/- in a pure 
background. Mice were maintained in the IBV-CSIC facility on a 12/12 light/dark cycle 
under constant temperature (23°C) with food and water provided ad libitum. 
Male mice of 16 days, 3 and 12 months of age were sacrificed by cervical dislocation. 
Brain was recovered and the two hemispheres separated, one conserved at -80ºC for 
processing for western blot and qPCR analyses, and the other fixed in 4% 
paraformaldehyde in phosphate buffer saline (PBS) for immunohistochemical analyses. 
 
Immunohistochemical analyses 
Dehydrated tissues from at least three independent mice per group were embedded in 
paraffin and sectioned at 4μm. Some sections were stained with periodic acid Schiff 
(PAS). Other sections were de-waxed, rehydrated, and warmed at 95ºC for 30 min in 
10 mM citrate buffer for antigen retrieval. Sections were blocked in blocking buffer (1% 
bovine serum albumin; 5% fetal bovine serum in PBS) and incubated overnight at 4ºC 
with the appropriate primary antibody diluted in blocking buffer: anti-GFAP (diluted 
1/300; Sigma ref. G3893, Saint Louis, MO, USA), Iba-1 (diluted 1/200; Waco ref. 019-
19741, Richmond, VA, USA) and anti-Cox2 (diluted 1/250; Cayman Chemicals ref. 
160107, Ann Arbor, MI, USA). After three washes of 10 min in PBS, sections were 
incubated for 1 h at room temperature with the corresponding biotin-conjugated anti-
rabbit or anti-mouse secondary antibody (Jackson ImmunoResearch, West Grove, PA, 
USA) diluted in blocking buffer, washed three times with PBS for 5 min and visualized 
with the Avidin–Biotin Complex (ABC) (Vectastain Elite ABC kit, Vector Laboratories, 
Burlingame, CA, USA) using diaminobenzidine as chromogenic substrate for 
peroxidase (Peroxidase substrate kit DAB; Vector Laboratories, Burlingame, CA, USA). 
Sections were slightly counterstained with hematoxylin (Sigma, Madrid, Spain), 
dehydrated, and mounted in DPX (Merck, Germany). Images were acquired by light 
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microscopy (Leica DM RXA2, Leica Microsystems, Wetzlar, Germany) and analyzed 
with Image J software (NIH, Bethesda, MD, USA). The intensity of the signal was 
quantified using the Image J software in an area of 0.17 mm2 located between the 
dentate gyrus and the CA1 region of the hippocampus, and expressed as the number 
of pixels/mm2. The significance level (Student’s t-test) was set at * p < 0.05, ** p < 0.01 
and *** p < 0.001.  
 
RNA purification 
Total RNA from the posterior part of the neocortex and hippocampus of WT, Epm2a-/- 
and Epm2b-/- animals aged 16 days, 3 months and 12 months (n=7 per group) was 
isolated with the Rneasy Lipid Tissue Mini Kit (Qiagen® GmbH, Hilden, Germany) 
following the manufacturer’s protocol. RNA concentration of each sample was 
measured using a NanoDrop™ Spectrophotometer (Thermo Fisher Scientific, 
Wilmington, DE, USA). RNA integrity number (RIN) was tested using the Agilent 2100 
BioAnalyzer (Agilent Technologies, Palo Alto, CA, USA).  
 
TaqMan qRT-PCR 
cDNA was prepared using the High-Capacity cDNA Reverse Transcription kit (Applied 
Biosystems, Foster City, CA, USA) following the protocol provided by the supplier. 
Parallel reactions for each RNA sample were run in the absence of MultiScribe 
Reverse Transcriptase to assess the lack of contamination of genomic DNA. TaqMan 
qRT-PCR assays were performed in duplicate for each gene on cDNA samples in 384-
well optical plates using an ABI Prism 7900 Sequence Detection system (Applied 
Biosystems, Life Technologies, Waltham, MA, USA). For each 10μL TaqMan reaction, 
4.5μL cDNA was mixed with 0.5μL 20x TaqMan Gene Expression Assays and 5μL of 2x 
TaqMan Universal PCR Master Mix (Applied Biosystems). The identification numbers 
and names of TaqMan probes are shown in Table I. The mean values of the three 
house-keeping genes, hypoxanthine-guanine phosphoribosyltranferase (Hprt), alanyl-
transfer RNA synthase (Aars) and X-prolyl aminopeptidase (aminopeptidaseP) 1 
(Xpnpep1), were used as internal controls for normalization. The reactions were carried 
out using the following parameters: 50°C for 2min, 95°C for 10min, and 40 cycles of 
95°C for 15sec and 60°C for 1min. Finally, all TaqMan PCR data were captured using 
the Sequence Detection Software (SDS version 2.2.2, Applied Biosystems). Samples 
were analyzed with the double-delta cycle threshold (∆∆CT) method. Results were 
analyzed with two-way ANOVA followed by Tukey’s post hoc or Student’s t-test when 
required. The significance level was set at * p < 0.05, ** p < 0.01 and *** p < 0.001.  
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Western blotting  
Mouse brain homogenates were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.0; 150 mM 
NaCl, 1% Nonidet P-40; 0.5% Na-deoxycholate; 0.1% SDS) supplemented with 
protease and phosphatase inhibitors (Roche, Germany). After centrifugation at 14,000 
g for 20 minutes at 4ºC (Ultracentrifuge Beckman with 70Ti rotor), supernatants were 
quantified with BCA reagent (Pierce, Waltham, MA, USA). Protein samples were mixed 
with loading sample buffer and heated at 95ºC for 5 min. Twenty g of proteins was 
separated by electrophoresis in SDS-PAGE gels and transferred to nitrocellulose 
membranes (200 mA per membrane, 80 minutes). Nonspecific binding was blocked by 
incubation in 5% non-fat milk in TBS containing 0.2% Tween for 1 hour at room 
temperature. The membranes were incubated at 4ºC overnight with primary antibodies: 
anti-IL1 (diluted 1:1000, Abcam, Cambridge, United Kingdom), anti-IL6 (diluted 
1:1000; Abcam, Cambridge, United Kingdom), anti-TNF (diluted 1:1000, Abcam, 
Cambridge, United Kingdom) and anti--actin (diluted 1:30,000; Sigma-Aldrich, St. 
Louis, MO, USA). Membranes were washed with TBS-T and incubated for 1h at room 
temperature with the appropriate horseradish peroxidase conjugated secondary 
antibody (1:2,000; Dako, Glostrup, Denmark). Immune complexes were revealed by 
incubating the membranes with chemiluminescence reagent 
(electrochemiluminescence; Amersham, GE Healthcare, Buckinghamshire, United 
Kingdom). Densitometries were carried out with Totallab software (TL100 v.2006b), and 
values were normalized using -actin levels. Normalized values were expressed as fold 
change from values obtained in WT aged 16 days samples.  
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Results 
 
Lafora inclusions in the telencephalon in Epm2a-/- and Epm2b-/- mice 
A few PAS-positive round or elongated inclusions in the neuropil and more rarely in the 
neuronal cytoplasm were first seen in transgenic mice aged 3 months. The number and 
size of the inclusions was higher in Epm2a-/- and Epm2b-/- mice aged 12 months as 
detailed elsewhere [16, 17]. Examples of these deposits are shown in Fig 1. 
 
Astrocyte and microglial responses in Epm2a-/- and Epm2b-/- mice 
We analyzed by immunohistochemistry the levels of GFAP (glial fibrillary acidic protein; 
a marker of reactive astrocytes) and Iba1 (ionized calcium-binding adapter molecule 1; 
a marker of reactive microglia) in selected brain areas from wild type (WT), Epm2a-/- 
and Epm2b-/- mice of 16 days, 3 months and 12 months of age. We observed that 
GFAP-immunoreactive astrocytes increased in number in the hippocampus (Fig. 2) and 
cerebral cortex (not shown) of Epm2a-/- and Epm2b-/- mice in comparison to WT 
littermates, at 3 and 12 months of age. No significant differences were found between 
Epm2a-/- and Epm2b-/- mice. Iba1-immunoreactive microglia also increased in number 
in Epm2a-/- and Epm2b-/- mice when compared to WT littermates at the age of 3 and 12 
months (Fig. 3). In addition, we found that the number of reactive microglial cells was 
greater in Epm2b-/- when compared to Epm2a-/- mice (Fig. 3). 
 
Gene expression of cytokines and mediators of the inflammatory response with 
aging in WT, Epm2a-/- and Epm2b-/- mice 
Since reactive astrocytes and microglia are mediators of the innate inflammatory 
response, we assessed the age-dependent expression of a panel of cytokines and 
mediators of the inflammatory response in wild type, Epm2a-/- and Epm2b-/- mice. First, 
we analyzed the regular age-dependent changes in the expression of these genes in 
wild type mice: we found that C3ar1, C4b, Csf3r, Ccl6, CxCl10, Il6, Il6st, Tnfrsf1a, 
Il10ra and Il10rb mRNA expression levels significantly increased and C1ql1 levels 
significantly decreased in WT mice of 3 months of age when compared with WT mice 
aged 16 days. The differences in the expression levels of these genes further 
increased in WT mice aged 12 months when compared with mice aged 16 days; in 
addition, Ccl3, Ccl4, Tlr4 and Tnfα mRNA expression was higher in WT mice aged 12 
months when compared with mice aged 16 days. However, Tgf-β1 decreased with age. 
Increased expression with age was supported to a greater extent by the fact that C4b, 
Ccl3, Ccl4, Ccl6, CxCl10, Il6, and Tnfα were significantly increased in WT mice aged 
12 months when compared with WT mice 3 months old (Table II).  
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In the case of Epm2a-/- mice, C3ar1, Csf3r, Ccl4, Il1b, Il6st, Il10ra, and Il10rb mRNAs 
were increased and C1ql1 mRNA was decreased in mice aged 3 months when 
compared with mice aged 16 days. Moreover, C3ar1, C4b, Csf1r, Csf3r, Tlr4, Ccl4, 
Ccl6, CxCl10, Il1b, Il6, Tnfα, Il10ra and Il10rb mRNAs were significantly increased in 
Epm2a-/- aged 12 months when compared with Epm2a-/- aged 16 days. C1ql1 mRNA 
also significantly decreased in Epm2a-/- mice aged 12 months. Finally, nine genes, 
C3ar1, C4b, Csfr1, Csf3r, Ccl6, CxCl10, Il1b, Il6 and Tnfα, were significantly up-
regulated in Epm2a-/- aged 12 months when compared with Epm2a-/- aged 3 months 
(Table II). 
Regarding modifications in gene expression with aging in Epm2b-/- mice, C3ar1, Ccl6, 
Il6, Il6st, and Il10rb mRNA expression was increased and C1ql1 mRNA levels were 
downregulated in mice aged 3 months when compared with 16-day-old mice. C3ar1, 
C4b, Csf3r, Tlr4, Ccl3, Ccl4, Ccl6, CxCl10, Il1b, Il6, Il6st, Tnf, Tnfrsf1a, Il10, Il10ra 
and Il10rb were significantly increased in Epm2b-/- mice aged 12 months when 
compared with Epm2b-/- mice aged 16 days. In contrast, a significant reduction in C1ql1 
mRNA levels was observed in Epm2b-/- mice aged 12 months when compared with 
younger animals. Differences with age were greater in Epm2b-/- when compared with 
Epm2a-/- mice, as thirteen genes instead of nine genes were significantly up-regulated 
in Epm2b-/- mice aged 12 months when compared with mice aged 3 months, including 
C3ar1, C4b, Tlr4, Tlr7, Ccl3, Ccl4, Ccl6, CxCl10, Il1b, Il6, Tnfα, Il10ra and Il10rb (Table 
II).  
 
Differential gene expression of cytokines and mediators of the inflammatory 
response in Epm2a-/- and Epm2b-/- mice compared with WT mice  
Then, we analyzed the differences in gene expression at the different ages between 
wild type, Epm2a-/- and Epm2b-/- mice. Few differences were seen in Epm2a-/- (laforin 
knock-out) and Epm2b-/- (malin knock-out) mice aged 16 days when compared with 
age-matched WT littermates; we found a small increase in the expression of Il6 and 
Tnfα in Epm2a-/- mice and a small increase in the expression of C1qtnf7, Csf3r and Il6 
in Epm2b-/- mice at this age (Table II). At 3 months of age we found an increase in the 
expression of Ccl4, CxCl10 and Il6st in Epm2a-/- mice, and of CxCCl10 and Tnfα in 
Epm2b-/- mice (Table II). In contrast, a significant reduction of Ccl4 and Il10ra occurred 
in Epm2b-/- when compared with Epm2a-/- mice at this age. However, a dramatic gene 
up-regulation was found in Epm2b-/- mice at the age of 12 months when compared with 
the limited change in Epm2a-/- mice at a similar age. Whereas only C3ar1, Csf3r and 
CxCl10 mRNA expression was increased in Epm2a-/- in comparison to WT, the 
expression of C3ar1, C4b, Ccl4, Ccl6, CxCl10, Il1b, Il6, Tnfα and Il10ra was up-
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regulated in Epm2b-/- aged 12 months when compared with age-matched WT (Table II). 
All these results are compatible with the presence of inflammation in the brain of LD 
mice at 3 months of age becoming aggravated as the mice aged, with the phenotype 
more severe in the case of Epm2b-/- mice. In fact, C3ar1, Ccl4, Ccl6, CxCl10, Il1b, tnf 
and Il10ra mRNA expression was significantly up-regulated in Emp2b-/- mice aged 12 
months when compared with Epm2a-/- mice of the same age (Table II). 
 
Protein expression of selected cytokines and mediators 
In order to confirm the inflammatory process present in the brain of Epm2a-/- and 
Epm2b-/- mice, IL1-β, IL6 and TNFα protein levels were analyzed by western blotting in 
brain extracts from wild type, Epm2a-/- and Epm2b-/- mice at the ages of 16 days, 3 
months and 12 months. As shown in Fig. 4, at 16 days of age Epm2b-/- mice showed an 
increase in the levels of IL1- and IL6 in comparison to WT mice. No differences were 
observed in the case of Epm2a-/- mice. At 3 months of age, we found in Epm2b-/- mice a 
tendency to higher levels of IL1- and IL6 and a significant increase in the levels of 
TNF in comparison to WT of the same age. However, Epm2a-/- mice showed similar 
protein levels of IL1- and IL6 and reduced levels of TNF- at this age in comparison to 
WT. At 12 months of age, Epm2b-/- mice showed higher levels of IL1- and IL6 but 
similar levels of TNF in comparison to WT of the same age. In contrast, Epm2a-/- mice 
showed levels of IL1-, IL6 and TNF similar to WT. These data confirm that Epm2b-/- 
mice present a more severe inflammatory pattern than Epm2a-/- mice. 
In addition, we analyzed the levels of cyclooxigenase 2 (Cox2), a target gene of 
inflammatory mediators. An immunohistochemical analysis of the hippocampus of WT, 
Epm2a-/- and Epm2b-/- mice of different ages showed an increase in the levels of Cox2 
in the case of Epm2a-/- and Epm2b-/- mice at 3 months of age, which dramatically 
increased at 12 months of age (Fig. 5), with the staining at this age more intense in the 
case of Epm2b-/- in comparison to Epm2a-/- mice. 
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Discussion 
Laforin knock-out (Epm2a-/-) and malin knock-out (Epm2b-/-) mice used in the present 
study [17, 31] start to develop LBs in cerebral cortex, hippocampus, basal ganglia, 
thalamus, cerebellum, cerebellar nuclei and brain stem at about the first month of age, 
and this increases in number and size with disease progression. LBs are very 
abundant in these regions at advanced stages of the disease [17, 31, 32]. Deposits are 
also found in the choroid plexus but the olfactory bulb is largely spared. Although both 
mouse lines have clinical symptoms similar to those seen in human LD, Epm2b-/- mice 
show some differences in comparison to Epm2a-/- mice such as reduced accumulated 
motor surface, rearing and stereotyped activity, as well as lower episodic memory 
deficits and non-spatial memory skills. In addition, although both mouse lines have 
tonic-clonic seizures, these occur in parallel with spike-wave, poly-spikes and poly-
spike-wave complexes in Epm2a-/- mice but there are no EEG correlates in Epm2b-/- 
mice [32]. All these data suggest that the phenotype observed in Epm2b-/- mice is more 
severe than that presented in Epm2a-/- mice. 
In this study, we investigated whether neuroinflammation is a novel hallmark in Lafora 
disease. With this aim, we analyzed how the expression of a panel of cytokines and 
mediators of the inflammatory response changes with age in WT, Epm2a-/- and Epm2b-
/- mice. It is known that marked modification of the profile of gene expression of 
cytokines and molecules linked with the inflammatory response occurs in the cerebral 
cortex and other brain regions of mice with age. This happens in normal aging and also 
in transgenic mice including APP/PS1, P301S-MAPT and S49P-Syracuse human 
neuroserpin (S49P-Syracuse), and in CJD-induced prionopathy in murine PrP-null mice 
expressing human PrP, which are models of human β-amyloidopathy reminiscent of 
Alzheimer disease, familial frontotemporal degeneration-tauopathy (FTLD-tau), 
neuroserpinopathy and Creutzfeldt-Jakob disease, respectively [33-36]. This pattern is 
repeated in our study as C3ar1, C4b, Csf3r, Tlr4, Ccl4, Ccl6, CxCl10, Il1b, Il6, Tnfα, 
Il10ra and Il10rb mRNA expression levels increase and C1ql1 levels significantly 
decrease in WT, Epm2a-/- and Epm2b-/- mice aged 12 months when compared with 
mice aged 16 days. At the same time, Ccl3, Il6st and Tgfb1 are increased only in WT 
and Epm2a-/- mice whereas Tnfrsf1a and Il10 increased only in Epm2b-/- mice.  These 
findings support the idea that gene expression of cytokines and mediators of the 
inflammatory response is modulated with age, albeit with genotypic variations.  
Focusing on pathologic states, inflammatory responses are increased in Epm2a-/- and 
Epm2b-/- mice when compared with WT littermates. C3ar1, Csf3r and CxCl10 are 
significantly increased in Epm2a-/- mice aged 12 months when compared with age-
matched controls. Curiously, inflammatory responses are greater in Epm2b-/- mice 
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when compared with Epm2a-/- mice, as C3ar1, C4b, Ccl4, Ccl6, CxCl10, Il1b, Il6, Tnfα 
and Il10ra mRNAs are significantly up-regulated in Epm2b-/- aged 12 months. In 
general terms, IL1-β, IL6 and TNFα protein levels are in accordance with the 
corresponding mRNA expression levels, with the Epm2b-/- genotype the most 
dramatically affected. However, a discrepancy exists between Tnfα mRNA and TNFα 
protein levels at the age of 3 months in Epm2a-/-. It can be suggested that unexpected 
reduced TNFα protein expression is related to epigenetic regulation. However there is 
no available information about non-coding RNAs in LD and related transgenic models. 
An explanation of this punctual finding at the age of 3 months in Epm2a-/- is not known. 
In agreement with increased expression of cytokines and mediators of the immune 
response in both LD mouse models, we found increased levels of Cox2, a protein with 
pro-inflammatory properties, in both Epm2a-/- and Epm2b-/- mice, although we observed 
higher protein levels in Epm2b-/- mice as the animals aged. 
We also present data indicating that the number of GFAP-immunoreactive astrocytes 
increases in Epm2a-/- and Epm2b-/- mice when compared with WT littermates, although 
this increase is similar in Epm2a-/- and in Epm2b-/- mice. Therefore, the extent of 
dysregulated gene expression of cytokines and mediators of the inflammatory 
response, which is higher in Epm2b-/- mice, cannot be explained by a differing number 
of reactive astrocytes. However, we also present evidence of an increase in Iba-1-
immunoreactive cells (microglia) in Epm2a-/- and Epm2b-/- mice, which is greater in 
Epm2b-/- mice in comparison to Epm2a-/- mice. This phenotype correlates with the 
increased gene expression of cytokines and mediators of the inflammatory response 
present in Epm2b-/- mice, suggesting involvement of reactive microglia in the severity of 
the inflammatory phenotype of Emp2b-/- mice.  
Therefore, and in agreement with previous data [32], the phenotype in Epm2b-/- mice is 
more severe than in the Epm2a-/- mice. The causes of the more severe phenotype in 
Epm2b-/- are not known but our present results clearly show a close relationship 
between stronger microglia-dependent inflammatory responses and the already 
described impaired motor function, memory and learning, together with the 
unpredictable seizures present in these mice. Microglia may have very disparate 
functions depending on the setting and stimulus [37], but chronic inflammation, 
involving chemokines, pro-inflammatory cytokines, anti-inflammatory cytokines and 
members of the complement system, is usually associated with nerve cell damage in 
human neurodegenerative diseases with abnormal protein aggregates and in related 
animals models. The observations presented in this study are particularly relevant 
since increased microglia and marked increase in mRNA and protein expression of 
cytokines and mediators of the inflammatory response are described for the first time in 
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LD, a paradigm of polyglucosan disease. Insoluble phosphorylated polyglucosans, 
endoplasmic reticulum stress, oxidative stress, altered autophagy and ubiquitin-
proteasome activity may all contribute to the inflammatory response. Since 
inflammatory responses appear at relatively early stages of LD, the administration of 
anti-inflammatory agents may be considered a possible treatment in order to delay 
brain damage.  
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Table I: TaqMan probes used for the study of expression of cytokines and mediators of 
the immune response in mouse, including probes used for normalization (Hprt, Aars 
and Xpnpep1). 
 
 
 
 
Table II: mRNA expression of selected cytokine-related genes involved in the 
inflammatory response in wild-type (WT), Epm2a-/- (laforin knock-out) and Epm2b-/- 
(malin knock-out) mice aged 16 days, 3 months and 12 months. Data are represented 
as the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 Epm2a-/- or Epm2b-/- 
compared with age-matched WT, ▫ p < 0.05, ▫▫ p < 0.01, ▫▫▫ p < 0.001 Epm2b-/-  
compared with Epm2a-/-, a p < 0.05, aa p < 0.01, aaa p < 0.001 compared with animals 
aged 16 days, b p< 0.05, bb p < 0.01, bbb p < 0.001 compared with animals aged 3 
months.  
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Figure legends 
 
Figure 1: Periodic acid-Schiff (PAS) staining of representative sections of the 
hippocampus of wild type (WT), Epm2a-/- (laforin knock-out) and Epm2b-/- (malin knock-
out) mice aged 16 days, 3 months and 12 months. A-I: scale bar in I = 150 µm; C1, F1, 
I1, scale bar in C1 = 15 µm. A few PAS-positive inclusions are seen in Epm2a-/- and 
Epm2b-/- at the age of three months. The number and size of inclusions augments at 
the age of 12 months.   
 
 
Figure 2: Glial fibrillary acidic protein (GFAP) immunohistochemistry of the 
hippocampus of wild type (WT), Epm2a-/- (laforin knock-out) and Epm2b-/- (malin knock-
out) mice aged 16 days, 3 months and 12 months. Paraffin sections slightly 
counterstained with hematoxylin. A-I, scale bar in I = 150 µm. The intensity of the 
signal was expressed as number of pixels/mm2. Data are the mean values from at least 
three independent mice; vertical bars indicate standard deviation. Marked increase in 
the number of astrocytes is observed in the CA1 region of the hippocampus in Epm2a-/- 
and Epm2b-/- mice when compared with WT at the age of 3 months and 12 months. 
Significant differences with respect to the corresponding WT are evaluated as * p<0.05, 
** p<0.01, *** p<0.001 compared with age-matched WT. ▫ p < 0.05 compared with 
Epm2a-/- (Student’s t-test). No significant differences were observed between Epm2a-/- 
and Epm2b-/- mice in any age group. 
 
Figure 3: Iba1 immunohistochemistry of the hippocampus of wild type (WT), Epm2a-/- 
(laforin knock-out) and Epm2b-/- (malin knock-out) mice aged 16 days, 3 months and 12 
months. Paraffin sections slightly stained with hematoxylin. A-I, scale bar in I = 170 µm. 
A1, E1 and I1, scale bar in A1 = 15 µm. The intensity of the signal was expressed as 
the number of pixels/mm2. Data are the mean values from at least three independent 
mice; vertical bars indicate standard deviation. Marked increase in the number of 
microglia is observed in the CA1 region of the hippocampus in Epm2a-/- and Epm2b-/- 
mice when compared with WT at the age of 3 months and 12 months. Significant 
differences with respect to the corresponding WT are evaluated as * p<0.05, ** p<0.01, 
*** p<0.001 compared with age-matched WT (Student’s t-test).  
 
Figure 4:  Western blot of IL1-β, IL6 and TNF-α in wild-type (WT), Epm2a-/- (laforin 
knock-out) and Epm2b-/- (malin knock-out) mice aged 16 days, 3 months and 12 
months. Data show an increase in IL1- and IL6 protein levels in Epm2b-/- aged 16 
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days and 12 months when compared with age-matched WT. A significant reduction in 
TNF-α protein levels occurred in Epm2a-/- and an increase in Epm2b-/- aged 3 months 
when compared to WT. β-actin is used as a control of protein loading. Data are 
presented as the mean ± SEM. * p < 0.05, ** p < 0.01 and *** p < 0.001 compared with 
age-matched WT. ▫ p < 0.05, ▫▫ p < 0.01, ▫▫▫ p < 0.001 compared with Epm2a-/-. a p < 
0.05, aa P < 0.01, aaa p < 0.001 compared with animals aged 16 days. b p< 0.05, bb p < 
0.01, bbb p < 0.001 compared with animals aged 3 months.   
 
Figure 5: Cox2 immunohistochemistry of the hippocampus of wild type (WT), Epm2a-/- 
(laforin knock-out) and Epm2b-/- (malin knock-out) mice aged 16 days, 3 months and 12 
months. Paraffin sections slightly stained with hematoxylin. A-I, scale bar in I = 170 µm, 
I1, scale bar = 15 µm. The intensity of the signal was expressed as the number of 
pixels/mm2. Data are the mean values from at least three independent mice; vertical 
bars indicate standard deviation. Marked increase in the levels of Cox2 is observed in 
the CA1 region of the hippocampus in Epm2a-/- and Epm2b-/- mice when compared with 
WT at the age of 3 months and 12 months. Significant differences with respect to the 
corresponding WT are evaluated as * p<0.05, ** p<0.01, *** p<0.001 compared with 
age-matched WT. ▫ p < 0.05 compared with Epm2a-/-; a p <0.05, aa P < 0.01 
compared with animals aged 16 day (Student’s t-test).  
